Sacubitril/Allisartan in hyperuricemia

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor Wei Zhang

Shanghai Institute of Hypertension of Ruijin Hospital, Shanghai (China)

3 More presentations in this session

Presentation thumbnail

Benefit-harm trade-offs of intensive blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of six pivotal randomized controlled trials.

Doctor X. Guo (Shenyang, CN)

Presentation thumbnail

Duration of blood pressure treatment and risk of major cardiovascular events

Professor K. Rahimi (Oxford, GB)

Presentation thumbnail

ADEL: A population-based study of clinical outcomes of aldosterone dysregulation

Professor R. Thomsen (Aarhus, DK)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: new treatments and biomarkers in hypertension

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Comparative clinical outcomes on renal function and mortality of uricosuric agents versus xanthine oxidase inhibitors in patients with hyperuricemia and cardiovascular risks

Congress Presentation

Effects of SGLT2 inhibitors on hyperuricemia in patients with chronic heart failure with reduced ejection fraction.

Congress Presentation

Mildly decreased egfr modifies the association between uric acid and risk of kidney function decline: a 5-year population-based cohort study

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources